Efficacy and safety of viva QS capsule for nicotine addiction in Malaysian adult smokers
We conducted a randomised, double-blind, placebo-controlled study to evaluate the effectiveness of Viva QS® capsule, a supplement consisting of twelve herbs, for the management of nicotine addiction. Smokers meeting study criteria were recruited into the study. Follow-up was undertaken for 6 mon...
| Main Authors: | , , , , |
|---|---|
| Format: | Proceeding Paper |
| Language: | English |
| Published: |
2010
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/22330/ http://irep.iium.edu.my/22330/4/pp18.pdf |
| _version_ | 1848778987910725632 |
|---|---|
| author | Mohamad Noor, Zaswiza Nik Mohamed, Mohamad Haniki Md Aris, Mohd Aznan Draman, Samsul Shaikh Rahman Bux, Siti Halimah Bux |
| author_facet | Mohamad Noor, Zaswiza Nik Mohamed, Mohamad Haniki Md Aris, Mohd Aznan Draman, Samsul Shaikh Rahman Bux, Siti Halimah Bux |
| author_sort | Mohamad Noor, Zaswiza |
| building | IIUM Repository |
| collection | Online Access |
| description | We conducted a randomised, double-blind, placebo-controlled study to evaluate the effectiveness of
Viva QS® capsule, a supplement consisting of twelve herbs, for the management of nicotine addiction.
Smokers meeting study criteria were recruited into the study. Follow-up was undertaken for 6 months,
with three assessment time points for smoking status andwithdrawal symptoms. Brief counseling was
provided at each follow-up via telephone call at week 4 and 12. At week 24, face-to-face follow-up was
done and self-reported abstinence was validated by measuring expired carbon monoxide level and
cotinine in urine and/or saliva samples. Result: Of 155 smokers recruited, mean age was 35.2 ± 8.36
years. Mean baseline Fagerström test for nicotine dependence (FTND) score was 5.03 ± 1.39. 7-days
point prevalence quit rate was 22.4% at week 24 [Viva QS = 30.7% vs. placebo = 13.9%]; p = 0.015; OR
= 2.74 (CI =1.197-6.282), 34.7% at week 12 [42.7% vs. 26.2%; p = 0.038, OR = 2.08 (CI = 1.04-4.16)
and 24.5% at week 12 [32% vs. 16.7%]; p =0.031; OR = 2.35 (CI = 1.07-5.17). Most common adverse
events reported were sore throat (Viva QS =28.8% vs. placebo = 36.6%), dry mouth (17.8% vs. 16.9%)
and cough (11% vs. 8.4%) There were no significant differences in all adverse events reported by subjects
in both groups. Conclusion: Viva QS ® at least doubled smoking cessation rate vs. placebo in smokers
with moderate to high level ofnicotine dependence without any significant adverse effects. |
| first_indexed | 2025-11-14T15:10:37Z |
| format | Proceeding Paper |
| id | iium-22330 |
| institution | International Islamic University Malaysia |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-14T15:10:37Z |
| publishDate | 2010 |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | iium-223302013-07-18T01:37:46Z http://irep.iium.edu.my/22330/ Efficacy and safety of viva QS capsule for nicotine addiction in Malaysian adult smokers Mohamad Noor, Zaswiza Nik Mohamed, Mohamad Haniki Md Aris, Mohd Aznan Draman, Samsul Shaikh Rahman Bux, Siti Halimah Bux RS Pharmacy and materia medica We conducted a randomised, double-blind, placebo-controlled study to evaluate the effectiveness of Viva QS® capsule, a supplement consisting of twelve herbs, for the management of nicotine addiction. Smokers meeting study criteria were recruited into the study. Follow-up was undertaken for 6 months, with three assessment time points for smoking status andwithdrawal symptoms. Brief counseling was provided at each follow-up via telephone call at week 4 and 12. At week 24, face-to-face follow-up was done and self-reported abstinence was validated by measuring expired carbon monoxide level and cotinine in urine and/or saliva samples. Result: Of 155 smokers recruited, mean age was 35.2 ± 8.36 years. Mean baseline Fagerström test for nicotine dependence (FTND) score was 5.03 ± 1.39. 7-days point prevalence quit rate was 22.4% at week 24 [Viva QS = 30.7% vs. placebo = 13.9%]; p = 0.015; OR = 2.74 (CI =1.197-6.282), 34.7% at week 12 [42.7% vs. 26.2%; p = 0.038, OR = 2.08 (CI = 1.04-4.16) and 24.5% at week 12 [32% vs. 16.7%]; p =0.031; OR = 2.35 (CI = 1.07-5.17). Most common adverse events reported were sore throat (Viva QS =28.8% vs. placebo = 36.6%), dry mouth (17.8% vs. 16.9%) and cough (11% vs. 8.4%) There were no significant differences in all adverse events reported by subjects in both groups. Conclusion: Viva QS ® at least doubled smoking cessation rate vs. placebo in smokers with moderate to high level ofnicotine dependence without any significant adverse effects. 2010 Proceeding Paper NonPeerReviewed application/pdf en http://irep.iium.edu.my/22330/4/pp18.pdf Mohamad Noor, Zaswiza and Nik Mohamed, Mohamad Haniki and Md Aris, Mohd Aznan and Draman, Samsul and Shaikh Rahman Bux, Siti Halimah Bux (2010) Efficacy and safety of viva QS capsule for nicotine addiction in Malaysian adult smokers. In: IIUM Research, Innovation & Invention Exhibition (IRIIE 2010), 26 - 27 January 2010, Kuala Lumpur. http://www.iium.edu.my/irie/10/sub10/author/list_p.php |
| spellingShingle | RS Pharmacy and materia medica Mohamad Noor, Zaswiza Nik Mohamed, Mohamad Haniki Md Aris, Mohd Aznan Draman, Samsul Shaikh Rahman Bux, Siti Halimah Bux Efficacy and safety of viva QS capsule for nicotine addiction in Malaysian adult smokers |
| title | Efficacy and safety of viva QS capsule for nicotine addiction in Malaysian adult smokers |
| title_full | Efficacy and safety of viva QS capsule for nicotine addiction in Malaysian adult smokers |
| title_fullStr | Efficacy and safety of viva QS capsule for nicotine addiction in Malaysian adult smokers |
| title_full_unstemmed | Efficacy and safety of viva QS capsule for nicotine addiction in Malaysian adult smokers |
| title_short | Efficacy and safety of viva QS capsule for nicotine addiction in Malaysian adult smokers |
| title_sort | efficacy and safety of viva qs capsule for nicotine addiction in malaysian adult smokers |
| topic | RS Pharmacy and materia medica |
| url | http://irep.iium.edu.my/22330/ http://irep.iium.edu.my/22330/ http://irep.iium.edu.my/22330/4/pp18.pdf |